Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

N. Shanmuganathan · SciRah

Researcher profile · Semantic Scholar

N. Shanmuganathan

Share profile

N. Shanmuganathan — researcher profile on SciRah

h-index: 19
Works: 104
Citations: 1,248

Most-cited papers

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease.
S. Branford, Paul P. S. Wang, D. Yeung, D. Thomson +29 more
2018Blood192 citations Open access
Semantic Scholar
Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
N. Shanmuganathan, I. Pagani, D. Ross, Sahee Park +8 more
2020Blood86 citations Open access
Semantic Scholar
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia
Y. Ochi, K. Yoshida, Ying-Jung Huang, Ming-Chung Kuo +31 more
2021Nature Communications85 citations Open access
Semantic Scholar
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
D. Ross, I. Pagani, N. Shanmuganathan, C. Kok +14 more
2018Leukemia78 citations
Semantic Scholar
Successful treatment‐free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells
Y. Irani, Amy Hughes, J. Clarson, C. Kok +6 more
2020British Journal of Haematology73 citations Open access
Semantic Scholar
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
M. Mauro, T. Hughes, Dong-Wook Kim, D. Réa +22 more
2023Leukemia51 citations Open access
Semantic Scholar
Asciminib: new therapeutic option in chronic phase CML with treatment failure.
D. Yeung, N. Shanmuganathan, T. Hughes
2022Blood45 citations Open access
Semantic Scholar
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission
I. Pagani, P. Dang, V. Saunders, R. Grose +14 more
2019Leukemia43 citations
Semantic Scholar
TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype.
D. Hiwase, C. Hahn, E. Tran, R. Chhetri +37 more
2022Blood41 citations Open access
Semantic Scholar
Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia
D. Thomson, N. Shahrin, Paul P. S. Wang, C. Wadham +6 more
2020Leukemia41 citations
Semantic Scholar
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
N. Shanmuganathan, C. Wadham, N. Shahrin, Jing-Hua Feng +20 more
2023Haematologica39 citations Open access
Semantic Scholar
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
N. Shanmuganathan, T. Hughes
2018Hematology. American Society of Hematology. Education Program39 citations Open access
Semantic Scholar
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
Shady Adnan Awad, O. Brück, N. Shanmuganathan, Timo Jarvinen +9 more
2022Blood Cancer Journal29 citations Open access
Semantic Scholar
Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study.
David T. Yeung, N. Shanmuganathan, John Reynolds, S. Branford +17 more
2024Blood26 citations
Semantic Scholar
Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission.
N. Shanmuganathan, Jodi A. Braley, A. Yong, D. Hiwase +4 more
2019Blood26 citations Open access
Semantic Scholar
Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome
N. Shanmuganathan, D. Hiwase, D. Ross
2017Leukemia and Lymphoma24 citations
Semantic Scholar
Management of TKI-resistant chronic phase CML.
T. Hughes, N. Shanmuganathan
2022Hematology. American Society of Hematology. Education Program22 citations Open access
Semantic Scholar
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia
A. Fernandes, N. Shanmuganathan, S. Branford
2022Cancers20 citations Open access
Semantic Scholar
Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
Y. Irani, C. Kok, J. Clarson, N. Shanmuganathan +5 more
2023Blood Advances19 citations Open access
Semantic Scholar
Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.
N. Shanmuganathan, D. Yeung, C. Wadham, A. Fernandes +17 more
2025Blood18 citations
Semantic Scholar
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial.
L. Estcourt, Zoe K McQuilten, Peter Bardy, M. Cole-Sinclair +496 more
2024The Lancet Haematology15 citations Open access
Semantic Scholar
The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort
N. Shanmuganathan, S. Branford, A. Yong, D. Hiwase +3 more
2018Blood14 citations Open access
Semantic Scholar
Beyond BCR::ABL1-The Role of Genomic Analyses in the Management of CML.
S. Branford, A. Fernandes, N. Shahrin, Muneeza Maqsood +2 more
2024The Journal of the National Comprehensive Cancer Network13 citations Open access
Semantic Scholar
Strong Association between Cancer Gene Variants at Diagnosis, Especially ASXL1, and Emergence of Kinase Domain Mutation-Driven Resistance in CML Patients Despite Frontline Treatment with More Potent BCR::ABL1 Inhibitors
N. Shanmuganathan, C. Wadham, David T. Yeung, N. Shahrin +10 more
2024Blood11 citations
Semantic Scholar
Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy.
I. Pagani, N. Shanmuganathan, P. Dang, V. Saunders +11 more
2023Blood10 citations
Semantic Scholar
The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?
N. Shanmuganathan, S. Branford
2019Current Hematologic Malignancy Reports10 citations
Semantic Scholar
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.
N. Shanmuganathan, S. Branford, T. Hughes, D. Hiwase
2019Blood Advances9 citations Open access
Semantic Scholar
Next-generation sequencing RNA fusion panel for the diagnosis of haematological malignancies.
T. Q. Ngo, Anna Fong Na Goh, P. Dorwal, Emmanuel Leong +7 more
2024Pathology (Sydney)8 citations
Semantic Scholar
RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia.
N. Shanmuganathan, C. Wadham, D. Thomson, N. Shahrin +16 more
2022Journal of Molecular Diagnostics8 citations Open access
Semantic Scholar
Asciminib for chronic myeloid leukaemia: Next questions
N. Shanmuganathan, T. Hughes
2022British Journal of Haematology8 citations
Semantic Scholar
Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia?
N. Shanmuganathan, Michael Osborn, Timothy P. Hughes
2025American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting7 citations
Semantic Scholar
Update of the Ascend-CML Study of Frontline Asciminib: High Rate of Optimal Response and Resistance Due to Mutations Is Rare
David T. Yeung, N. Shanmuganathan, Agnes S. M. Yong, J. Shortt +17 more
2024Blood7 citations
Semantic Scholar
Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML
S. Branford, C. Wadham, N. Shanmuganathan, A. Fernandes +15 more
2023Blood7 citations
Semantic Scholar
Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment‐free remission
Liu Lu, C. Kok, P. Dang, S. Branford +5 more
2022British Journal of Haematology7 citations
Semantic Scholar
NGS in CML - New standard diagnostic procedure?
S. Branford, N. Shanmuganathan
2019HemaSphere7 citations Open access
Semantic Scholar
Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study
D. Yeung, A. Grigg, N. Shanmuganathan, I. Cunningham +18 more
2018Blood7 citations Open access
Semantic Scholar
Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia
L. Chee, N. Lee, A. Grigg, Melissa Chen +8 more
2024Internal medicine journal (Print)6 citations Open access
Semantic Scholar
Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia
L. Chee, Nora Lee, A. Grigg, Melissa Chen +5 more
2022Blood6 citations Open access
Semantic Scholar
Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML
Mikko Purhonen, Mikael Tatun, Katariina Luukkainen, Kevin Hung +18 more
2025Leukemia5 citations Open access
Semantic Scholar
Accelerated-phase CML: de novo and transformed.
N. Shanmuganathan, Timothy P. Hughes
2023Hematology. American Society of Hematology. Education Program5 citations
Semantic Scholar
Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study
David T. Yeung, N. Shanmuganathan, J. Reynolds, S. Branford +19 more
2023Blood5 citations Open access
Semantic Scholar
Molecular monitoring in CML: how deep? How often? How should it influence therapy?
N. Shanmuganathan, Timothy P. Hughes
2018Blood5 citations
Semantic Scholar
Increased Inflammatory Cytokines in Plasma Are Associated with Sustained Treatment-Free Remission in Chronic Myeloid Leukaemia
C. Kok, V. Saunders, N. Shanmuganathan, Liu Liu +17 more
2024Blood4 citations
Semantic Scholar
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
C. Kok, V. Saunders, P. Dang, N. Shanmuganathan +4 more
2023Blood Cancer Journal4 citations Open access
Semantic Scholar
Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML
D. Yeung, N. Shanmuganathan, J. Reynolds, S. Branford +17 more
2022Blood4 citations Open access
Semantic Scholar
Multiplex technologies for the assessment of minimal residual disease and low‐level mutation detection in leukaemia: mass spectrometry versus next‐generation sequencing
N. Shanmuganathan, S. Branford
2021British Journal of Haematology4 citations
Semantic Scholar
Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes
N. Shanmuganathan, C. Wadham, N. Shahrin, D. Thomson +11 more
20204 citations Open access
Semantic Scholar
Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study
D. Yeung, N. Shanmuganathan, A. Grigg, I. Cunningham +17 more
2019Blood4 citations Open access
Semantic Scholar
Long-term survival gains after allogeneic hematopoietic stem cell transplant are driven by reductions in non-relapse mortality: A 35-Year Statewide Australian cohort study.
Alia Cibich, Gauri Wechalekar, N. Shanmuganathan, Deepak Singhal +7 more
2026Transplantation and Cellular Therapy3 citations Open access
Semantic Scholar
TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
M. Shah, C. Hahn, E. Tran, Kirsty M Sharplin +24 more
2022Blood3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

S. Branford×33
Invite
S. Branford — researcher profile on SciRah
D. Yeung×21
Invite
D. Yeung — researcher profile on SciRah
D. Ross×16
Invite
D. Ross — researcher profile on SciRah
T. Hughes×16
Invite
T. Hughes — researcher profile on SciRah

×15

Invite

T. Hughes — researcher profile on SciRah

Invite

C. Kok — researcher profile on SciRah

Invite

A. Yong — researcher profile on SciRah

V. Saunders×12

Invite

V. Saunders — researcher profile on SciRah

Invite

C. Wadham — researcher profile on SciRah

Invite

N. Shahrin — researcher profile on SciRah

Invite

D. Hiwase — researcher profile on SciRah

Jodi A. Braley×8

Invite

Jodi A. Braley — researcher profile on SciRah